03 November 2003
Radiofrequency heat ablation for lung tumors: potential applications
Prashant N. Chhajed, Michael TammMed Sci Monit 2003; 9(11): ED5-7 :: ID: 13272
Abstract
Radiofrequency ablation (RFA) is an image guided percutaneous procedure using thermal energy that is used to treat malignant lesions in various organs including liver, breast and lungs. It has also been used bronchoscopically to treat endobronchial tumors. Current passing through tissue from the active electrode leads to ion agitation, which is converted by means of friction into heat leading to irreparable cellular damage and coagulation necrosis. The potential benefits include decreased cost and morbidity, treating patients who are not surgical candidates due to age, co-morbidity or extent of disease and the possibility of performing the procedure on an outpatient basis. The aim is usually to reduce tumor size. Whether it can be used with a curative intent in well localized primary tumors remains to be determined by well designed studies. However, caution should be exercised because selective tumor resection is not the gold standard to treat potentially resectable lung malignancies that are treated with lobectomy. Obviously, lung volume reduction surgery combined with tumor resection has challenged this approach. RFA might be the treatment of choice for multiple lung metastases that are usually approached surgically for long-term remission. A specific indication may also be bilateral pulmonary metastases. Other potential applications might be tumor size reduction by a non-surgical procedure followed by adjuvant chemotherapy. Currently, these thoughts remain only speculations, until proven by clinical trials with medium to long-term follow up. Furthermore, the risk of this procedure for pulmonary application has to be better defined.
Keywords: Catheter Ablation - methods, Electrodes, Hyperthermia, Induced, Ions, Lung Neoplasms - therapy, Necrosis
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Preoperative Blood Transfusion Requirements for Hemorrhoidal Severe Anemia: A Retrospective Study of 128 Pa...Med Sci Monit In Press; DOI: 10.12659/MSM.943126
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952